Latest Articles
GSK presents positive data for B7-H4-targeted ADC in gynecological cancers - GSK US
GSK presents positive data for B7-H4-targeted ADC in gynecological cancers GSK US
Published: April 12, 2026, 2:25 p.m.
GSK presents positive data for B7-H4-targeted ADC in gynecological cancers - GSK
GSK presents positive data for B7-H4-targeted ADC in gynecological cancers GSK
Published: April 12, 2026, 2:25 p.m.
Eiza González reveals triple diagnosis threatens motherhood? - MSN
Eiza González reveals triple diagnosis threatens motherhood? MSN
Published: April 12, 2026, 12:13 p.m.
Toronto researchers use AI to tackle endometriosis diagnostic delays - CTV News
Toronto researchers use AI to tackle endometriosis diagnostic delays CTV News
Published: April 12, 2026, 9 a.m.
Are microplastics affecting your fertility? The silent threat of plastic in the ovaries - theweek.in
Are microplastics affecting your fertility? The silent threat of plastic in the ovaries theweek.in
Published: April 12, 2026, 8:53 a.m.
Woman Creates Wellness Network After Life Challenges Transform Mindset - world.infonasional.com
Woman Creates Wellness Network After Life Challenges Transform Mindset world.infonasional.com
Published: April 12, 2026, 6:15 a.m.
Woman Gets Endometriosis Diagnosis After Years of ‘Debilitating’ Pain, Calls Treatment Options 'Barbaric’ - AOL.com
Woman Gets Endometriosis Diagnosis After Years of ‘Debilitating’ Pain, Calls Treatment Options 'Barbaric’ AOL.com
Published: April 12, 2026, 2:13 a.m.
Trastuzumab Pamirtecan Elicits Responses in HER2-Expressing Advanced/Metastatic Endometrial Cancer - OncLive
Trastuzumab Pamirtecan Elicits Responses in HER2-Expressing Advanced/Metastatic Endometrial Cancer OncLive
Published: April 11, 2026, 6:14 p.m.
BioNTech's Trastuzumab Pamirtecan Achieves Positive Phase 2 Results in Advanced HER2-Expressing Endometrial Cancer - Quiver Quantitative
BioNTech's Trastuzumab Pamirtecan Achieves Positive Phase 2 Results in Advanced HER2-Expressing Endometrial Cancer Quiver Quantitative
Published: April 11, 2026, 11:10 a.m.
BioNTech and DualityBio’s Antibody-Drug Conjugate Trastuzumab Pamirtecan Demonstrated Clinically Meaningful Efficacy in Patients with HER2-Expressing, Recurrent Endometrial Cancer - The Manila Times
BioNTech and DualityBio’s Antibody-Drug Conjugate Trastuzumab Pamirtecan Demonstrated Clinically Meaningful Efficacy in Patients with HER2-Expressing, Recurrent Endometrial Cancer The Manila Times
Published: April 11, 2026, 11:01 a.m.
Link copied to clipboard!